Literature DB >> 7841038

The proliferation of multiple myeloma colonies (MY-CFUc) in vitro is independent of prognosis and is not associated with mutated N- or K-ras alleles in human bone marrow aspirates.

B C Millar1, J B Bell, R Barfoot, M Everard.   

Abstract

During the period September 1987 to March 1993 the proliferation of myeloma cells as colonies (MY-CFUc) in vitro was examined in bone marrow aspirates from 43 patients with multiple myeloma and two patients with Waldenström's macroglobulinaemia. Twenty-four samples from 45 patients, of whom three were at presentation, four were in complete remission (CR), six had achieved a partial response (PR) and 11 had progressive disease (PD), produced MY-CFUc in vitro. The same bone marrow aspirates or one taken within 2 months of that assessed for MY-CFUc were used in the polymerase chain reaction (PCR). Genomic DNA was analysed for mutations in N- and K-ras by slot blotting of the amplified products from the PCR with 32P-labelled probes and by direct sequencing. No mutations were detected in N- or K-ras proto-oncogenes at codons 12, 13 or 61 in any sample. Eleven of the patients from whom MY-CFUc were produced remain alive with a median survival of 73 months (range 15-75 months). MY-CFUc have been cultured from 19 of these 24 patients on subsequent occasions, of whom nine remain alive. Among patients whose cells did not produce MY-CFUc in vitro at the time of sampling for mutated ras alleles, biopsy samples from four patients have produced MY-CFUc in vitro on subsequent occasions, of whom one patient remains alive. The data show that the proliferation of MY-CFUc in vitro occurred independently of disease status and was not indicative of prognosis. The failure to detect mutated N- or K-ras alleles in any sample suggests that if such mutations were present in the cells which form colonies in vitro they represented less than 0.1% of the tumour burden and did not affect the survival of this group of patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7841038      PMCID: PMC2033582          DOI: 10.1038/bjc.1995.53

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  26 in total

1.  Oncogenes in multiple myeloma: point mutation of N-ras.

Authors:  R L Paquette; J Berenson; A Lichtenstein; F McCormick; H P Koeffler
Journal:  Oncogene       Date:  1990-11       Impact factor: 9.867

2.  Interleukin-6 is a cofactor for the growth of myeloid cells from human bone marrow aspirates but does not affect the clonogenicity of myeloma cells in vitro.

Authors:  A M Borinaga; B C Millar; J B Bell; J K Joffe; J L Millar; R Gooding; P Riches; T J McElwain
Journal:  Br J Haematol       Date:  1990-12       Impact factor: 6.998

3.  Correlated flow cytometric analysis of H-ras p21 and nuclear DNA in multiple myeloma.

Authors:  H Tsuchiya; J Epstein; P Selvanayagam; J R Dedman; G Gallick; R Alexanian; B Barlogie
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

4.  Analysis of RAS oncogene mutations in human lymphoid malignancies.

Authors:  A Neri; D M Knowles; A Greco; F McCormick; R Dalla-Favera
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

5.  The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing.

Authors:  H G Ahuja; A Foti; M Bar-Eli; M J Cline
Journal:  Blood       Date:  1990-04-15       Impact factor: 22.113

6.  Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes.

Authors:  C J Farr; R K Saiki; H A Erlich; F McCormick; C J Marshall
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

7.  Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas.

Authors:  M Kawano; T Hirano; T Matsuda; T Taga; Y Horii; K Iwato; H Asaoku; B Tang; O Tanabe; H Tanaka
Journal:  Nature       Date:  1988-03-03       Impact factor: 49.962

8.  Ras oncogene expression and DNA content in plasma cell dyscrasias: a flow cytofluorimetric study.

Authors:  M Danova; A Riccardi; G Ucci; R Luoni; M Giordano; G Mazzini
Journal:  Br J Cancer       Date:  1990-11       Impact factor: 7.640

9.  Evidence that multiple myeloma may be regulated by homeostatic control mechanisms: correlation of changes in the number of clonogenic myeloma cells in vitro with clinical response.

Authors:  J A Maitland; B C Millar; J B Bell; A Montes; J Treleaven; M E Gore; T J McElwain
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

10.  Ras oncogene mutation in multiple myeloma.

Authors:  A Neri; J P Murphy; L Cro; D Ferrero; C Tarella; L Baldini; R Dalla-Favera
Journal:  J Exp Med       Date:  1989-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.